Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Human amnion epithelial stem cells (hAESC) are a type of stem cell derived from the amniotic membrane, currently being investigated by Indonesia University (Universitas Indonesia) for the treatment of infertility caused by a thin endometrium. This regenerative medicine approach involves the isolation of hAESC from donor amniotic membranes, which are then seeded onto an amnion bilayer biological graft. This construct is transplanted into the patient's uterus to promote the regeneration and recovery of the endometrial lining. The hAESC are characterized by pluripotency markers such as Oct 3/4, Nanog, SSEA-4, and TRA-1-60, and are selected for being HLA-DR negative to minimize the risk of immune rejection. The therapy aims to restore endometrial thickness and receptivity, potentially improving implantation rates in patients with permanent endometrial scarring or thinness.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on human amnion epithelial stem cells.